Page last updated: 2024-08-24

fluorodeoxyglucose f18 and maytansine

fluorodeoxyglucose f18 has been researched along with maytansine in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aftimos, P; Ameye, L; Awada, A; Brouwers, AH; de Vries, EG; Emonts, P; Flamen, P; Garcia, C; Gebhart, G; Guiot, T; Hoekstra, OS; Huizing, M; Lamberts, LE; Menke-van der Houven van Oordt, CW; Oyen, WJ; Schröder, CP; Stroobants, S; Tol, J; Vugts, DJ; Wimana, Z	1

Trials

1 trial(s) available for fluorodeoxyglucose f18 and maytansine

Article	Year
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:4 Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; In Situ Hybridization, Fluorescence; Maytansine; Middle Aged; Positron-Emission Tomography; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2016

Article

Year

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.

Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:4

Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; In Situ Hybridization, Fluorescence; Maytansine; Middle Aged; Positron-Emission Tomography; Receptor, ErbB-2; Trastuzumab; Treatment Outcome

2016